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A new simple, precise and accurate high performance liquid chromato-
graphy (HPLC) method was developed and validated for the simulta-
neous determination of irinotecan (CPT-11) and two related compounds
viz., 7-ethyl-10-hydroxycamptothecin (SN-38) and camptothecin (CPT)
in pharmaceutical dosage forms. Chromatography was accomplished
using a reversed-phase C18 column and ultraviolet (UV) detection and
an isocratic mobile phase consisting of 3 % v/v triethylammonium acetate
buffer (pH 3) and acetonitrile (70:30 v/v). The linear range of quantitation
for all the compounds was 0.1-10 µg/mL. The limit of quantitation for
all the compounds ranged between 0.01-0.05 µg/mL. The method has
the requisite accuracy, selectivity, sensitivity and precision to assay of
CPT-11 and related compounds in pharmaceutical dosage forms and
bulk API.
Key Words: Irinotecan, Camptothecin, High performance liquid
chromatography-ultra violet, 7-Ethyl-10-hydroxycamptothecin.
INTRODUCTION
Camptothecin (CPT) is a natural, water-insoluble quinoline alkaloid produced
by the plant Camptotheca acuminata that is indigenous to China. Camptothecin has
been chemically modified to produce other anticancer agents including irinotecan
(CPT-11)1. Irinotecan is essentially a prodrug and is hydrolyzed by carboxylesterases
to form the active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38)2. These
compounds exit as two coexisting forms viz., the active lactone form and an inactive
carboxylate form which has no topoisomerase I inhibitive activity. The lactone form
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has a closed α-hydroxy-δ-lactone ring, which can be hydrolyzed to form an open-
ring hydroxylic acid (carboxylate form) (Fig. 1). Under acidic conditions (pH < 5)
the lactone structure predominates, whereas at pH values above 8 the carboxylate
is present exclusively3. High-performance liquid chromatography coupled with fluoro-
metric1-11 detection and mass spectrometry12,13 have been used for the quantitation
of these compounds as the intact lactone-carboxylate or as a total form in buffered
solutions and in biological matrices including plasma, red blood cells, saliva, urine,
faeces, microsomes and in tumor tissues. A review of these methods when focusing
on CPT-11 and its major metabolite, SN-38 as compounds of interest reveal important
difference including the matrices from which they are isolated, separation mode
i.e., isocratic or gradient elution, buffer type, sample preparation, stationary phase,
additives and/or ion pairing agents. The in vitro analysis of CPT-11 in IV solutions
is necessary to ensure that products of suitable quality are manufactured and made
available to the public. Furthermore in vitro analytical methods for CPT-11 are
vital for the evaluation of new formulations of the CPT-11. Such methods may be
necessary for determining encapsulation efficacy or the in vitro release characteristics
of particulate delivery systems of CPT-11. Therefore there is a need for a simple
analytical method for the determination of CPT-11 and its related compounds during
product development studies. In this study we report the development and validation
of a simple isocratic HPLC method for the determination of the lactone form of the
CPT-11 and its main related compounds (SN-38 and CPT) in commercial products
using UV detection.
Compound R1 R2 
CPT-11 
 
C2H5 
CPT H H 
SN-38 OH C2H5 
 
 Fig. 1. Structure of the lactone and carboxylate forms of CPT-11, CPT and SN-38
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EXPERIMENTAL
Irinotecan (CPT-11) hydrochloride trihydrate, 7-ethyl-10-hydroxycamptothecin
(SN-38) and camptothecin (CPT) were purchased from Aurisco Pharmaceutical
(Shanghai, China). HPLC-grade acetonitrile was purchased from Merck (Darmstadt,
Germany). Triethylammounium acetate (TEAA) buffer was purchased from Fluka
(Switzerland). Citric acid and boric acid were purchased from Merck (Darmstadt,
Germany). Camptosar® injectable solutions containing 100 mg/5 mL CPT-11 HCl
was obtained from the Sobhan Chemotherapeutics Company (Rasht, Iran). Water
was purified using a Milli-Q® UV plus System (Millipore, Bedford, MA, USA).
All other reagents were at least of analytical reagent grade and used without further
purification.
Chromatographic analyses were performed using an Agilent® HPLC system
(Agilent Technologies, USA) that was comprised of a degasser (Model G1322A),
quaternary pump (Model G1311A), autosampler system (Model G1329A) and a
diode-array detector (Model G1315B). Chemstation® software (Rev.B.02.01-SR1
[260]) was used for data monitoring and analysis. The sample injection volume
was 20 µL and separation of the compounds of interest was achieved using a
Nucleosil® RP-18 (5 µm, 250 mm × 4 mm) analytical column protected by a C18
Nucleosil® guard column (5 µm, 4 mm × 4 mm) and a mobile phase consisting of 3 %
v/v triethylammonium acetate (TEAA) buffer (pH 3) and acetonitrile (70:30 v/v) at
a flow rate of 1 mL min-1. All samples and the column compartment were maintained
at an ambient temperature of 25 °C and the eluant was monitored using UV detection
at 254 nm. The mobile phase was filtered through a 0.45 µm Chrom. Tech. Nylon-66
filter prior to use.
Preparation of stock and standard solutions: Stock solutions (100 µg/mL)
of CPT-11, SN-38 and CPT were prepared in ethanol (99.9 % v/v). Standard solutions
(0.1, 1, 2, 5 and 10 µg/mL) of each of the compounds were prepared by pipetting
appropriate aliquots of the relevant stock solution and making up to volume with
the TEAA buffer solution.
Preparation of injections for analysis: Samples of commercial product were
prepared for analysis by emptying the contents of 10 Camptosar® vials into a volum-
etric flask after which the solution was mixed well. An aliquot of the resultant
solution equivalent to the volume of one injection was added into each of six 100 mL.
A grade volumetric flasks made up to the volume with the TEAA buffer solution
and mixed for a further 2 min. A 50 microlitre aliquot of the dilute solution was
transferred to a 10 mL A grade volumetric flask and made up to the volume with
the TEAA buffer solution to yield an approximate concentration of CPT-11 of 5 µg/mL
which falls in the previously described range of linearity for this method.
RESULTS AND DISCUSSION
HPLC method development and optimization: The retention times for CPT-11,
SN-38 and CPT using the previously described chromatographic conditions were
5.7 ± 0.14, 11.9 ± 0.12 and 14.7 ± 0.10 min (n = 40), respectively. Representative
3968  Mohammadi et al. Asian J. Chem.
chromatograms for CPT-11, SN-38 and CPT are shown in Fig. 2. The retention of
all compounds was dependant on the strength of the buffer used to prepare the
mobile phase and the pH of that buffer. In an attempt to control peak tailing, due to
interaction between the analytes and underivatized silanols on the column wall,
triethylammonium acetate was used. At pH values above 3.5 silanols act as weak
acids react strongly with basic compounds, thereby delaying elution of the peaks of
interest and resulting in peak broadening and tailing.
 Fig. 2. A representative chromatogram of a standard solution containing CPT-11, SN-38
and CPT
Validation: The method was validated with respect to the followng parameters
including linearity, limit of quantitation and limits of detection (LOQ and LOD),
precision, accuracy, selectivity and recovery.
Linearity: Peak area of the compounds of interest were plotted versus concen-
tration and least squares linear regression analysis performed on the resultant curve.
The calibration curves constructed for CPT-11, SN-38 and CPT were found to be
linear over the concentration range of 0.1-10 µg/mL with mean correlation coeffi-
cients (r) > 0.999 with % RSD values ranging from 0.2 to 3.5 % obtained following
linear regression analysis.
LOQ and LOD: LOQ was determined based on signal-to-noise ratios and
were selected using an analytical response of 10 times the background noise14. The
LOQ was found to be 10, 50 and 25 ng/mL for CPT-11, SN-38 and CPT, respectively.
The LOD was determined based on signal-to-noise ratios and was selected based
on analytical responses of 3 times the background noise. The LOD was found to be
4, 15 and 9 ng/mL for CPT-11, SN-38 and CPT, respectively.
Precision: The precision of the assay was investigated with respect to both
repeatability and reproducibility. Repeatability was assessed by injecting replicate
samples (n = 9) of each of the 0.1, 1 and 10 µg/mL standards. Inter-day precision
was assessed by injecting the same standards (n = 3) on three consecutive days.
Within- and inter-day precision data are summarized in Table-1.
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TABLE-1 
PRECISION AND ACCURACY OF THE HPLC METHOD IN MEASURING  
KNOWN CONCENTRATIONS OF CPT-11, SN-38 AND CPT 
With within-day (n = 6) Between-day (n = 6) 
Co
m
po
u
n
d 
Target 
concentration 
(µg mL-1) 
Observed 
concentration 
(mean ± SD) 
RSD 
(%) 
Accuracy 
(%) 
Observed 
concentration 
(mean ± SD) 
RSD 
(%) 
Accuracy 
(%) 
0.1 0.098 ± 0.003 3.06 98.00 0.102 ± 0.003 2.94 102.00 
1.0 1.023 ± 0.01 0.97 102.30 0.985 ± 0.012 1.22 98.50 CPT-11 
10.0 9.82 ± 0.15 1.53 98.20 9.790 ± 0.05 0.51 97.90 
0.1 0.101 ± 0.002 1.98 101.10 0.1015 ± 0.0025 2.46 101.50 
1.0 1.016 ± 0.02 1.96 101.60 1.022 ± 0.021 2.05 102.20 SN-38 
10.0 10.02 ± 0.10 1.00 100.20 10.0 ± 0.03 0.30 100.00 
0.1 0.103 ± 0.003 2.90 103.00 0.10± 0.0025 2.50 100.00 
1.0 0.997 ± 0.002 0.23 97.00 1.03 ± 0.015 1.45 103.00 CPT 
10.0 10.17 ± 0.22 2.16 101.72 10.25 ± 0.035 0.34 102.50 
 
Accuracy: The accuracy of the assay was assessed by interpolation of replicate
peak areas of three accuracy standards (0.1, 1 and 10 µg/mL) of each compound
from a calibration curve prepared as previously described. In each case, the per cent
relative error was calculated and is summarized in Table-1. Accuracy was determined
as the per cent error by which the mean concentration of the replicate samples
deviated from the known target concentration as described below: (mean concentration/
target concentration × 100). The accuracy of the assay ranged from 97-103 % at the
concentrations assessed for all analytes (Table-1).
Selectivity: Typical chromatograms developed following the analysis of CPT-11,
SN-38 and CPT are shown in Fig. 2 and clearly reveal the selectivity of the method
for separation of irinotecan and its related compounds. Photodiode array detection
was used to provide additional evidence of the selectivity of the method, and to
evaluate the homogeneity of the each of the peaks of interest. Chromatographic
peak purity data was obtained from the spectral analysis report and peak purity
values of greater than 0.999 indicated the presence of an homogenous peak for the
compounds under investigation.
Recovery: Spiked samples of CPT-11, SN-38 and CPT were prepared by addition
of standard solutions to placebo injections at different percentages of the expected
concentration of each compound in dilute injection solutions. Each vial of Camptosar®
injection (100 mg/5 mL) contains 225 mg sorbitol NF powder and 4.5 mg of lactic
acid (USP-grade) at a pH of 3.0-3.815. Mean recoveries were found to be above
99.65 % at low concentration and above 99.85 % at high concentrations (Table-2).
Assay: The proposed method was applied to the determination of CPT-11 in
Camptosar® injections. A typical chromatogram obtained following the assay of
Camptosar® injections is depicted in Fig. 3. The results of this analysis yielded
102.4 % (% RSD = 1.12 %) of label claim indicating that the method is suitable for
the selective analysis of CPT-11 and is free from interference of excipients used in
this dosage form.
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TABLE-2 
MEAN RECOVERY OF CPT-11, SN-3 AND CPT AT LOW (n = 6)  
AND HIGH (n = 6) CONCENTRATIONS OF THE ANALYTES 
Analyte CPT-11 SN-38 CPT 
Low Concentration    
Concentration (µg mL-1) 0.1 0.1 0.1 
Mean recovery (%) 99.65 101.13 98.71 
RSD (%) 1.25 2.70 3.01 
High Concentration    
Concentration (µg mL-1) 10 10 10 
Mean recovery (%) 100.18 101.27 99.55 
RSD (%) 0.45 1.25 1.05 
 
 Fig. 3. Resultant chromatograms following the analysis of a standard solution of (A) CPT-
11 (5 µg/mL) and (B) Camptosar® injection showing CPT-11(1)
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Conclusion
In summary, a simple HPLC method is developed and validated for simultaneous
determination of CPT-11, SN-38 and CPT in commercial products of CPT-11. The
method is fast, efficient and has simple sample preparation procedure. The total
analytical time for all analytes is less than 15 min which is an advantage for in vitro
analysis. Rapid analyses reduce the risk of degradation and conversion of analytes
during sample preparation and analysis.
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